ESMO 2022 | Results of a Phase I/II study of ipi, nivo and trabectedin as 1L therapy for advanced LMS

Erlinda Gordon, MD, Cancer Center of Southern California/Sarcoma Oncology Center, Santa Monica, CA, presents results of a Phase I/II study evaluating the combination of ipilimumab, nivolumab, and trabectidin as first-line (1L) therapy for advanced leiomyosarcoma (LMS). First-line combinatorial therapy with ipilimumab, nivolumab, and trabectedin may be more effective than standard first-line therapy, and safer than standard first-line therapy for advanced LMS. Randomized Phase II studies are planned to confirm these findings. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.